SGK1 and plasma cell myeloma: In multiple myeloma, complement C3a activates osteoclasts through the PI3K/PDK1/SGK1 pathway, and the inhibition of SGK1 using EMD638683 significantly reduces osteoclastogenesis, providing a new therapeutic target and strategy for the treatment of multiple myeloma patients [151].